Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 7/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.51 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | TRIM24 | O15164 | 2/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6605977 | 0.85 | CYP11B1 (0.38) | CYP11B1CYP11B2CYP19A1CYP3A4BRD4 | |
| SCHEMBL4156212 | 0.85 | CYP11B1 (0.48) | CYP11B1CYP11B2CYP19A1CYP3A4ALDH1A1 | |
| SCHEMBL6073571 | 0.83 | CYP11B2 (0.47) | CYP11B1CYP11B2CYP19A1CYP3A4BRD4 | |
| SCHEMBL6609493 | 0.82 | CYP11B1 (0.39) | CYP11B1CYP11B2CYP19A1CYP3A4BRD4 | |
| SCHEMBL6608644 | 0.80 | CYP11B2 (0.37) | CYP11B1CYP11B2CYP19A1CYP3A4BRD4 | |
| SCHEMBL6605512 | 0.79 | CYP11B1 (0.51) | CYP11B1CYP11B2CYP19A1CYP3A4ALDH1A1 | |
| SCHEMBL6074168 | 0.78 | CYP11B1 (0.40) | CYP11B1CYP11B2CYP19A1CYP3A4ALDH1A1 | |
| SCHEMBL6603785 | 0.77 | ALDH1A1 (0.47) | CYP11B1CYP11B2CYP19A1CYP3A4ALDH1A1 | |
| SCHEMBL6073521 | 0.76 | CYP11B2 (0.39) | CYP11B1CYP11B2CYP19A1CYP3A4BRD4 | |
| SCHEMBL6074083 | 0.73 | ATAD2 (0.48) | CYP11B1CYP11B2ALDH1A1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1175417-B1 | SUBSTITUTED BENZOLACTAM COMPOUNDS | PFIZER PROD INC (US) | 2004-01-07 | — | — | EP | claimed |
| US-20030105124-A1 | Substituted benzolactam compounds | SOBOLOV-JAYNES SUSAN BETH (US) | 2003-06-05 | — | — | US | claimed |
| JP-2002544128-A | — | — | 2002-12-24 | — | — | JP | claimed |
| EP-1175417-A1 | SUBSTITUTED BENZOLACTAM COMPOUNDS | Pfizer Products Inc. (US) | 2002-01-30 | — | — | EP | claimed |
| WO-2000068224-A1 | SUBSTITUTED BENZOLACTAM COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2000-11-16 | — | — | WO | claimed |
| US-7119207-B2 | Benzoamide piperidine containing compounds and related compounds | PFIZER INC (US) | 2006-10-10 | — | — | US | disclosed |
| EP-1175417-B1 | SUBSTITUTED BENZOLACTAM COMPOUNDS | PFIZER PROD INC (US) | 2004-01-07 | — | — | EP | disclosed |
| US-20030105124-A1 | Substituted benzolactam compounds | SOBOLOV-JAYNES SUSAN BETH (US) | 2003-06-05 | — | — | US | disclosed |
| US-20030087925-A1 | Benzoamide piperidine containing compounds and related compounds | PFIZER INC. | 2003-05-08 | — | — | US | disclosed |
| EP-1272484-A2 | BENZOAMIDE PIPERIDINE COMPOUNDS AS SUBSTANCE P ANTAGONISTS | Pfizer Products Inc. (US) | 2003-01-08 | — | — | EP | disclosed |
| EP-1175417-A1 | SUBSTITUTED BENZOLACTAM COMPOUNDS | Pfizer Products Inc. (US) | 2002-01-30 | — | — | EP | disclosed |
| WO-2001077100-A2 | BENZOAMIDE PIPERIDINE COMPOUNDS AS SUBSTANCE P ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2001-10-18 | — | — | WO | disclosed |
| WO-2000068224-A1 | SUBSTITUTED BENZOLACTAM COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2000-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105124-A1 | Substituted benzolactam compounds | NPY1R, HAX1, CBR1 | CYP11B1 510/4885CYP11B2 487/4885CYP19A1 1658/4885 |
| US-20030087925-A1 | Benzoamide piperidine containing compounds and related compounds | TACR1, VIPR1, VIPR2 | CYP11B1 2904/4885CYP11B2 3109/4885CYP19A1 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.